Following the initial expansion of its Laval research centre in
1997, Boehringer Ingelheim is adding more new laboratories through 2007,
increasing its facilities by over 40 percent. This further substantial
investment of $36 million will allow Boehringer Ingelheim to add 40 new
high-calibre scientists to a world-class team of over 140 researchers
engaged in antiviral drug discovery.
[ILLUSTRATION OMITTED]
The Laval centre is one of four principal research centres within
the Boehringer Ingelheim Corporation's global research
organization. The new laboratories, including state-of-the-art level 2
and 3 biosafety laboratories, will incorporate the cutting-edge
technologies essential to maintaining Boehringer Ingelheim's
position as a pharmaceutical research and drug discovery leader. This
further growth will facilitate new high-level research initiatives for
the Canadian centre, which are primarily devoted to discovering and
developing new and effective medicines for HIV infections and hepatitis
C. Boehringer Ingelheim will realize its ambitious objectives in
collaboration with researchers and through continuing exchanges and
collaboration with the academic community, biotech companies, and
research institutes across Canada.
Boehringer Ingelheim
COPYRIGHT 2007 Chemical Institute of
Canada Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2007, Gale Group. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.